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Abstract
Background: Genomic rearrangements or structural variants (SVs) are one of the most common classes of
mutations in cancer.
Methods: An integrated DNA sequencing and transcriptional profiling (RNA sequence and microarray gene
expression data) analysis was performed on six ovarian cancer patient samples. Matched sets of control (whole
blood) samples from these same patients were used to distinguish cancer SVs of germline origin from those arising
somatically in the cancer cell lineage.
Results: We detected 10,034 ovarian cancer SVs (5518 germline derived; 4516 somatically derived) at base-pair level
resolution. Only 11 % of these variants were shown to have the potential to form gene fusions and, of these, less
than 20 % were detected at the transcriptional level.
Conclusions: Collectively our results are consistent with the view that gene fusions and other SVs can be significant
factors in the onset and progression of ovarian cancer. The results further indicate that it may not only be the
occurrence of these variants in cancer but their regulation that contributes to their biological and clinical
significance.
Background
Cancer genomes are characterized by the presence of
several classes of somatic mutations including point
mutations, copy number alterations and chromosomal
rearrangements or structural variants [1, 2]. Of these,
SVs are the most frequent [3–5] and include tandem-
duplications, inversions, deletions, insertions and
inter-chromosomal translocations [1]. Although can-
cer genomes may harbor hundreds to thousands of
SVs, only a handful are considered of potential func-
tional significance, typically involving protein-coding
genes [6–8]. Functionally significant SVs often involve
gene fusions that place protein-coding genes under
novel regulatory controls and/or result in the gener-
ation of novel fusion proteins [9–11]. A well-known
example is the reciprocal translocation between
chromosome 9 and 22 resulting in expression of the
BCR-ABL fusion protein in chronic myeloid leukemia
[12–14].
Advances in the application of the paired-end (or
mate-pair) approach to high-throughput sequencing
have made genome-wide surveys of genomic rearrange-
ments possible [6, 15–18] and recent studies have un-
covered a number of new gene fusions and other SVs
of potential functional significance in a variety of can-
cer genomes [7, 8, 19–21]. However, the potential im-
portance of gene fusions and other SVs to cancer onset
and progression may be modulated if these variants are
not expressed. Indeed, recent studies have revealed that
“normal” tissues can harbor transcriptionally repressed
“pro-neoplastic” SVs that only become oncogenic when
transcriptionally activated [22]. Thus, to fully evaluate
the functional significance of gene fusions and other
SVs in cancers, DNA sequence analyses should ideally
be coupled with transcriptional profiling. In an effort
to address this issue, we utilized an integrated compu-
tational workflow to analyze DNA sequencing and tran-
scriptional profiling (RNA sequence and microarray gene
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expression data) data from six ovarian cancer patient sam-
ples. In addition, DNA sequence data from matched sets
of control (whole blood) samples from these patients were
used to distinguish cancer SVs of germline origin from
those arising somatically in the cancer cell lineage. We
report here the detection of 10,034 ovarian cancer SVs
(5518 germline derived; 4516 somatically derived) at
base-pair level resolution. Only 11 % of these variants
were found to have the potential to form gene fusions
and, of these, less than 20 % were detected at the tran-
scriptional level. Collectively, our results demonstrate the
presence of large numbers of germline and somatically
derived gene fusions and other SVs in ovarian cancer tis-
sues and underscores the potential importance of the
regulation of gene fusions in cancer onset and progression.
Methods
Sequencing data acquisition
All specimens were obtained from patients with appropri-
ate consent from the relevant institutional review board.
Whole genome sequencing (WGS) data for six ovarian ser-
ous cystadenocarcinoma and matched somatic control
(whole blood) samples were selected from The Cancer
Genome Atlas (TCGA) data portal [23] using dbGAP in
BAM file format. These six patients were selected because
DNA-Seq, RNA-seq and gene expression microarray data
were available for each of these patients. The WGS data
consisted of 22 billion (range 1.3–2.54 billion) 75–100 bp
long paired-end reads (in forward-reverse orientation)
generated from the Illumina GAII instrument. The RNA-
Seq data consisted of 1 billion (range 105–243 million)
75 bp long paired-end reads also generated from the Illu-
mina GA II system. Samples and sequencing data are sum-
marized in Additional file 1: Table S1. BAM files
containing the sequencing data were sorted using Picard
Tools [24] SortSam and converted to FastQ format using
BamToFastQ program [25].
Genomic SV detection using WGS
Massive amounts of whole genome sequencing data
present a challenge in detecting complex structural
variants with high-accuracy. In order to accurately
detect and characterize genomic structural variants,
we designed a streamlined workflow (summarized in
Additional file 2: Figure S1) as follows:
SV detection
The overall quality of the WGS reads was assessed
using FastQ. Low quality (Q < 20) bases and adapter se-
quences were removed from the ends of the reads. The
remaining reads were aligned to the human reference
genome hg19 (GRCh37 assembly, UCSC genome data-
base) using Bowtie2 [26]. Unmapped reads were stored
in a separate file. PCR duplicates were removed from the
alignment files using the Picard Tools [24] MarkDuplicate
program. Since highly repetitive/low complexity genomic
regions may result in ambiguous or low confidence align-
ments, we conservatively filtered out all alignments with
mapping quality (MAPQ) < 35. Various classes of large
structural variants (SVs) were detected using SVDetect
[27]. The SVDetect algorithm searches for clusters of
paired-end reads creating distinct signatures of structural
variants in the alignment file. SV signatures are called if
any or both of the inherent characteristics of paired-end
sequencing constraints (i.e., library insert-size, alignment
orientation of mates relative to each other) are violated.
Based on the clusters of paired-end signatures, the SV
calls are generated and the location of breakpoints is
estimated. Genomic loci involved in a SV (a.k.a.“links”) are
required to be supported by a minimum number of
paired-end reads as determined by the sequencing depth
of coverage [28]. Since our samples have different sequen-
cing depths of coverage, different cutoff values were deter-
mined for each sample (Additional file 3: Table S2).
Filtering
We observed that more than 50 % of the SV calls were
‘small_duplications’ that could be the result of artifacts
generated during the library preparation. Thus, we conser-
vatively removed such calls as well as those described as
‘co-amplicons’ and ‘undefined’ calls generated from am-
biguous paired-end signatures. We additionally removed
all SV calls that had more than 50 % overlap with the low-
complexity genomic regions. Since, reference human gen-
ome quality is questionable around the centromere and
telomere regions and near the assembly gaps, we also re-
moved SVs mapping within 100-kilo base-pairs of these re-
gions. Finally, we removed all called SVs that mapped
either to mitochondrial or Y chromosome or currently un-
localized regions of the genome (“Un”, “hap”, etc.).
Targeted assembly of SVs
The paired-end read approach for SV detection does not
provide base-pair level breakpoint information but rather
provides genomic regions that may contain potential
breakpoints. Also, short (75 – 100 bp) read mapping to
the reference genome may generate false clusters of
paired-end reads resulting in false SV calls. In order to
confirm SV calls generated by SVDetect and to establish
breakpoints at the base-pair resolution, we performed a
targeted de novo assembly for each SV call. De novo
assembly is performed by progressively merging redundant
DNA sequences with shared overlapping ends determined
by a pre-specified parameter called ‘k-mer’ length. The
goal is to reconstruct the exact DNA sequence underlying
the SV. For the assembly of each SV call, we included se-
quencing reads mapping within the 500 bps on either side
of the genomic regions involved in a SV call. Also included
Mittal and McDonald BMC Medical Genomics  (2015) 8:40 Page 2 of 12
are reads that initially could not be mapped to the refer-
ence genome. Since a complete assembly cannot be
achieved using single k-mer length, we performed multiple
k-mer length assemblies by varying k-mer from half of the
read length (37–50 bp) to the complete read length (75–
100 bps) in 2 bp increments. Multiple k-mer assemblies
were performed using ABySS [29] and later merged using
Trans-ABySS [30] that also removes redundant assembled
sequences from the assembly. In order to further expand
the assembly set, we performed multiple k-mer assemblies
using an additional assembly program, Velvet [31].
Validation and breakpoint detection
Assembled DNA sequences (also called contigs) were
mapped to the human reference genome (hg19) using
the BWA [32] program that independently aligns
sections or fragments of a DNA sequence to discrete
genomic loci. Such mapping is called split-mapping.
Genomic coordinates of the paired-end based SV calls
from SVDetect were compared with the fragmented
alignments of the assembled contigs and breakpoints
were determined for SV calls supported by the assembly.
For each SV, two breakpoints are detected each corre-
sponding to the genomic locus participating in the SV
formation. Validation and breakpoint detection were car-
ried out using our previously developed pipeline, R-SAP
(RNA-Seq analysis pipeline; [33]), that accurately detects
fragmented alignments (split-mapping) representing
potential gene fusions and/or genomic rearrangements.
R-SAP modules were slightly modified to include intra-
genic SVs such as deletions and insertions and other
complex SV signatures such as transpositions that were
not detected in the original R-SAP configuration. In
order to minimize false SV calls supported by the assem-
bly, the assembled contigs were aligned to the reference
human genome using an additional alignment algorithm
SSAHA2 [34], and the SVs again validated using R-SAP.
The result is a stringently defined set of SVs with break-
points detected at the base-pair level resolution.
Fusion transcript detection using RNA-Seq
RNA-Seq reads obtained from TCGA were initially sub-
jected to quality and adapter filtering using FastQC and
TrimGalore [35]. Reads were subsequently aligned to the
reference human genome in paired-end mode using
TopHat (‘fusion-search’ mode). TopHat-fusion [36]
searches for potential breakpoints using the ‘split-read’
alignment of sequencing reads were supported by add-
itional ‘paired-end’ reads. Potential fusions reported by
TopHat were further validated using reference transcript
annotations established as a merged set of Ensembl (version
73) and lncRNAs available from the UCSC genome data-
base [37–39]. Finally, we required that each fusion be sup-
ported by at least one split-read and one paired-end read
alignment. We conservatively discarded fusions where both
ends of the fusion were confined to single gene loci.
Gene-expression analysis
We downloaded gene-expression microarray data for the
same 6 ovarian cancer samples using the TCGA data portal.
Due to the unavailability of gene expression data from
matched normal samples from the cancer patients exam-
ined, we utilized as controls, the results of assays carried
out on normal ovarian tissues collected from eight healthy
(age matched) women. These data were also downloaded
from the TCGA portal. The microarray expression data
were generated by RNA hybridization to Affymetrix
HT_HG-U133A gene chips and data files were provided in
‘cel’ format. Expression values were estimated and normal-
ized by the RMA normalization method from the cel files
using the Affymetrix Expression Consol [40]. For each
gene, the average expression values across all of the eight
normal samples were used as the denominator (numerator
was expression values determined for each cancer sample)




More than 10,000 structural variants (SVs) were identified
in the six ovarian cancer patient samples
DNA sequencing data of matched sets of six ovarian
serous cystadenocarcinoma and six somatic control
(whole blood) tissues (Additional file 1: Table S1) were
downloaded from the The Cancer Genome Atlas data
portal [23] using dbGAP in BAM file format. The raw
data consisted of 22 billion 75–100 bp paired-end reads
(range 1.3–2.54 billion; Additional file 1: Table S1). An
integrated computational workflow was developed to
facilitate the data analysis (Additional file 2: Figure S1;
see Methods for details).
Initial alignments resulted in the mapping of 84 % of
the DNA-Seq reads to the human reference genome (hg
19). A subsequent series of stringent filtering and valid-
ation steps (see Methods) resulted in a total of 35,721
SV calls. To confirm these SVs and to determine break-
points at base-pair level resolution, targeted de novo as-
sembly was performed for each SV call (Additional file
2: Figure S2). After correcting for multiplicity of con-
firmed SVs (presence of the same SV across multiple
samples), a total of 14,719 unique SVs were detected
across all samples (Additional file 4: Table S3). Of these,
32 % (4,685) were uniquely present in the somatic con-
trol (blood) samples, 31 % (4,516) were uniquely present
in the cancer samples and 37 % (5518) were present in
both the control (blood) and the cancer samples (Fig. 1a;
Additional file 2: Figure S3). We classified SVs detected
in both the cancer and somatic control (blood) samples
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as germline derived cancer variants since the presence
of precisely the same SV in divergent somatic cell types
implies a common clonal (germline) origin. Those SVs
detected exclusively in the cancer samples were classi-
fied as somatically derived cancer variants arising in the
cancer cell lineage. By these criteria, 5518 or 55 % of the
10,034 SVs detected in the cancer samples were germ-
line derived and 4516 or 45 % were somatically derived.
The SVs detected in the cancer samples were com-
prised of seven structural classes: inversions, transposi-
tions, tandem-duplications (100–10 million bps in size),
deletions (>20 bps), insertions (>20 bps), inverted-
duplications, and translocations. The distribution of
these SVs across all cancer samples is summarized in
Fig. 1b. The most frequent class of SVs was deletions
and germline derived deletions were twice as frequent
than somatically derived deletions. Germline and somat-
ically derived inversions and transpositions were present
in approximately equal frequencies while somatically
derived SVs were more frequent than germline derived
variants for all other classes of SVs (insertions, inverted-
duplications, tandem duplications and translocations).
Mutations in BRCA1 and/or BRCA2 genes are known
to be associated with genomic instability due to defi-
ciencies in homologous recombination repair [41].
While we detected no BRCA mutations within the
germlines of the patients analyzed in this study, the
tumor tissues of two patients displayed somatic muta-
tions in BRCA2 (Patient P2: frame shift DEL; Patient P5:
missense mutation). However, we detected no signifi-
cant elevation in the overall number of SVs between
patients P2 and P5 and the other patients analyzed in
the study.
Analysis of the frequency of recurrence of SVs across
the cancer samples indicates that, as expected, germline
derived SVs occur across multiple samples at the highest
frequency (Fig. 2). Indeed, more than half (3059/5518 or
55 %) of the germline derived SVs are present in mul-
tiple cancer patient samples reflecting naturally occur-
ring variation in the human population. In contrast, only
Fig. 1 a The number (percentage) of germline and somatically derived ovarian cancer SVs in six ovarian cancer patient samples. Circles represent
the total number of SVs detected in somatic control (whole blood; blue circle) and cancer (red circle) tissue samples collected from six ovarian
cancer patients. SVs identified in both the control and cancer samples were classified as germline derived, while SVs detected in only the cancer
samples were classified as somatically derived. b Distribution of SVs across structural categories. Somatically derived (red) and germline derived
(green) SVs were further categorized according to the underlying genomic rearrangement. Deletions were the most abundant category
accounting for the majority (~71 %; see percentages on top of bars) of the germline derived SVs. Corresponding data are shown in the Table
(top right corner). InvDupli: inverted-duplications, TandemDupli: tandem-duplication
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6 % (284/4516) of the somatically derived SVs were
detected in more than one cancer patient sample. These
SVs could represent identical somatic mutations that
have arisen recurrently across multiple OC patients or,
perhaps more likely, variants that are segregating in
the natural population but were in such low frequency
in our germline samples as to go undetected in the
sequencing analysis.
Ovarian Cancer SVs can be divided into 3 groups based
upon the location of chromosomal breakpoints
Detected SVs were annotated using a combined set of
224,555 normal reference transcripts (Ensembl annotations,
release 73 and lncRNAs from the UCSC genome database).
We classified SVs detected in our cancer samples into three
groups based on the location of breakpoints relative to the
reference transcripts as follows (Figs. 3 and 4a; see also
Additional file 2: Figure S4): intergenic SVs are defined as
variants with breakpoints mapping to two genes at dis-
tant genomic locations and at least one that overlaps
with an annotated gene; intragenic SVs are variants
with breakpoints mapping within a single annotated
gene; and gene-desert SVs are variants with break-
points mapping to distant locations within genomic re-
gions devoid of annotated genes (“gene deserts”).
Intragenic SVs are the most abundant class (50 %;
5,031/10,034) followed by gene-desert (39 %; 3,942/
10,034) and intergenic (11 %; 1,061/10,034) SVs. Inter-
genic SVs are >2X more abundant among somatically
derived variants than among germline derived variants
(677 vs. 384; Fig. 4b) while the number of intragenic
(2,151 vs. 2,880) and gene-desert SVs (1,688 vs. 2,254)
display more similar in frequencies among somatically
derived and germline derived variants.
Intergenic SVs encompass multiple classes of fusion-genes
We further divided intergenic SVs based on the loca-
tion of breakpoints within the various gene regions, i.e.,
the promoter region (defined as breakpoint regions
within 5 kb up-steam of the transcriptional start site),
the 5′ and 3′ untranslated leader regions (UTRs), and
the protein coding sequence (CDS). Intergenic SVs
where the 5′- partner gene sequence is fused with ei-
ther a non-protein coding gene (e.g., lncRNA) or with
an unannotated region of the genome (gene-desert) are
classified as 5′ truncated SVs. Finally, intergenic vari-
ants that do not manifest canonical gene structures (5′
UTR-promoter-CDS-3′UTR), display gene components
in incorrect orientation (e.g., 5′ UTR-CDS-promoter-3′
UTR; gene desert-3′ CDS, etc.) or otherwise cannot be
functionally evaluated were classified as uncharacter-
ized RNA (Additional file 5: Table S4).
The relative distribution of these sub-classes of inter-
genic SVs in the cancer samples is shown in (Fig. 5a).
The most abundant (37 %, 398/1061) sub-class of inter-
genic variants is associated with alterations in the pro-
moter region of genes. These altered promoter variants
along with the less frequent alternative 5′ UTR (4 %, 45/
1061) and 3′ UTR (7 %, 74/1061) sub-classes all have
the potential to alter the expression of associated genes
without altering coding sequences. Intergenic SVs asso-
ciated with the coding regions of genes also have the
potential to alter the expression levels (e.g., the 5′ part-
ner gene typically provides the promoter region in
addition to 5′ coding sequences while the 3′ partner
may bring novel microRNA binding sites in its 3′ UTR)
but may also generate novel fusion proteins if reading
frames are maintained. While only 5 % (52/1061) of the
intergenic SVs involve the fusion of coding regions of
different genes, 38 % (20/52) of these variants were in
frame. Interestingly, the vast majority of the in-frame
gene fusions (85 %, 17/20) were somatically rather than
germline derived suggesting that these de novo SVs have
either been selectively favored in the cancer cell lineages
or selected against in germline lineages or both. The
majority of the coding region inter-gene fusions (62 %,
32/52) were out-of-frame.
Fig. 2 Multiplicity of SVs across samples. The X-axis represents multiplicity (number of occurrences) of somatically derived (red bars) and germline
derived (green bars) SVs across cancer samples. The Y-axis represents percentage of SVs present in a particular multiplicity. The table presents the
numerical distribution of SVs across the cancer samples
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The breakpoints of most intragenic SVs map to introns
The intragenic class of SVs was sub-divided into those
with breakpoints mapping completely within the same
intron (intronic) and those where at least one breakpoint
mapped to an exon (exonic). The vast majority of intra-
genomic SVs (94 %, 4,744/5,031) were intronic (Fig. 5b;
Additional file 6: Table S5). Although intronic variants
may affect splicing functions, they do not affect coding
regions per se. Only 6 % (287/5,031) of the intragenic
SVs grouped into the exonic sub-class. The majority of
these exonic variants (138/287 or 48 %) mapped to non-
coding genes (e.g., lncRNAs) and are thus of currently
undefined significance. The breakpoints of the remaining
exonic variants mapped predominantly within 5′ or 3′
UTRs (5′UTRs: 17/287 or 6 %; 3′UTRs: 64/287 or
22 %). These intragenic variants could potentially alter
regulatory sequences involved in gene expression (e.g.,
upstream regulatory sequences in 5′UTRs or
microRNA binding sites in 3′UTRs). The breakpoint of
24 % (68/287) of the exonic variants mapped to coding re-
gions (CDS), which are presumed to disrupt the ORF and
are labeled “disruptive” (Additional file 6: Table S5).
Many of the SVs detected in ovarian cancer map to gene
desert regions
Although nearly 39 % (3,942/10,034) of the detected SVs
were classified as gene-desert variants, their potential
functional significance cannot be reliably inferred since
the structure of transcriptional units within gene-desert
regions is currently unknown.
Gene expression analyses
A minority of intergenic SVs is transcribed
Intergenic SVs have the potential to generate function-
ally significant gene fusions. Thus, in an effort to explore
the extent to which this class of SVs was being expressed
in our cancer samples, we downloaded from the TCGA
data portal the results of RNA sequencing (RNA-Seq)
and microarray (Affymetrix) profiling studies carried out
Fig. 4 Distribution of SVs across classes. a Distribution of total
detected SVs among classes. b Distribution of intergenic SVs
between somatically derived and germline derived SVs. Intergenic
SVs are significantly enriched (p-value < 0.05) for somatically
derived variants
Fig. 3 Classification of ovarian cancer SVs based on breakpoints. SVs
are depicted by black-grey boxes, reference transcripts are repre-
sented by the blue and green boxes. Thick boxes represent open-
reading-frame or coding sequences (CDS) while thin boxes represent
UTRs. a Intergenic SVs – breakpoints map to annotated genes
located at distant genomic locations; (b) intragenic SVs- break-
points map within the same gene; (c) gene desert- breakpoints
map to un-annotated genomic regions (gene deserts)
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on these same samples. The raw RNA-Seq data consisted
of 1 billion 75 bp paired-end reads (range 105–243 mil-
lion) (Additional file 1: Table S1). These data were again
analyzed using the computational workflow outlined in
Additional file 2: Figure S1 (see Methods for details).
Since intergenic SVs with breakpoints mapping to the
promoter region (398/1061) cannot be qualitatively
distinguished using the RNA-Seq data, they were not
part of the RNA-Seq analysis but are included in the
microarray expression analysis described below. All
other classes of intergenic SVs (coding region, 5′ trun-
cated, alternative 5′ UTR, alternative 3′ UTR and
uncharacterized RNAs) are included in the RNA-Seq
analysis. The breakpoints of these fusion transcripts
were detected in the RNA-Seq data using split-read
mapping (see Methods). Since introns are spliced out
during mRNA processing and are thus absent in the
RNA-Seq data, we adjusted intronic SV breakpoints to
the closest exon included in the gene fusion. SVs were
categorized as detected by RNA-Seq if transcripts were
found in at least 1 of the 6 cancer samples examined. Based
on this criterion, 16 % (103/663) of these potential gene
fusions were found to be expressed in the cancer samples.
The percentage of the transcribed germline derived fusions
(19 %, 30/158) was slightly higher than the somatically
derived fusions (15 %, 73/505) (Table 1; Additional file 1:
Table S1 and Additional file 7: Table S6).
Only somatically derived coding sequence gene fusions
are expressed
Of the 45 coding-gene fusions identified by the DNA-
Seq analysis, only 8 were detected by RNA-Seq and all
of these fusions were somatically derived (Table 1). Six
of the 8 expressed fusions were in frame. In-frame
fusions typically result in novel-fusion proteins that
bring different protein domains together. We analyzed
the rearrangement of protein domains resulting from
the 6 in-frame gene fusions using the SMART database
[42]. The fusion-gene structures and protein domain ar-
rangements are shown in Fig. 6.
Two of the six in-frame gene fusions, FARP1-SLC15A1
(13q32.2 inversion) and RP1-27O5.3–ZNF643 (1p34.2 -
1p35.1 deletion), resulted in a novel juxtaposition of
protein-coding domains. The domains associated with
the FARP1-SLC15A1 fusion are involved in a variety of
signal transduction pathways that have previously been
shown to influence cell-cell adhesion, cell migration and
morphogenesis [43]. Similarly, the BTB/POZ domain
Fig. 5 Distribution of intergenic and intragenic ovarian cancer SVs. a Distribution of germline and somatically derived intergenic SVs; (b)
Distribution of intronic and exonic intragenic SVs
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(Broad-Complex, Tramtrack and Bric-a-brac) contained
within the region of the RP1-27O5.3 gene involved in
the RP1-27O5.3–ZNF643 fusion has been previously im-
plicated in ovarian cancer growth and recurrence [44].
The potential functional significance of the remaining 4
somatically derived coding region gene fusions is cur-
rently unknown (Fig. 6). Other classes of transcribed
intergenic SVs include alternative 5′ UTRs (4 %, 2/45),
alternative 3′ UTRs (9 %, 7/74), 5′-truncated (19 %, 39/
208), and uncharacterized RNAs (17 %, 47/284) (Table 1;
Additional file 7: Table S6).
Microarray analysis
Intergenic SVs with breakpoints mapping within the
promoter region or within the 5′ or 3′ UTRs leave
coding regions unchanged but may be expected to
alter patterns of gene expression. In order to search
for possible quantitative changes in expression associ-
ated with these intergenic SVs, we utilized the results
of gene-expression microarray (Affymetrix HT_HG-
U133A) analyses downloaded from the TCGA data
portal for the same 6 ovarian cancer patient samples
(Note that the 5′-truncated, coding-region and
uncharacterized RNA fusions are not distinguishable
in microarray studies and thus were analyzed exclu-
sively in the RNA-Seq analyses discussed above).
Since gene expression profiles of normal ovarian
tissue from these patient samples are not available,
we downloaded and utilized as controls the results of
gene expression microarray profiles of normal ovarian
tissue from 8 other age-matched women (Additional
file 8: Table S7). Expression values were computed
and normalized using the RMA normalization of the
cel file data employing the Affymetrix Expression
Consol. Fold-change in expression relative to the
average of the 8 normal samples was computed for
each of the genes associated with intergenic altered
promoters, as well as altered 5′ and 3′ UTRs SVs
(Additional file 7: Table S6). Fold changes > 2X be-
tween control and cancer samples were considered
significant. The numbers of SVs displaying significant
changes by this criterion are displayed in Table 1.
Of the 517 (249 somatically derived and 268 germline
derived) gene fusions (promoter, alternative 5′UTR and
alternative 3′ UTR only) analyzed, 13 % (42 somatically
derived + 25 germline derived)/517) were differentially
expressed (Table 1) including 31 that were up regulated
and 36 that were down-regulated relative to controls
(Additional file 7: Table S6).
Chromosomal translocations are most frequently
associated with changes in gene expression
Chromosomal translocations are the physical basis of
nearly all gene fusions and we found them to be the
most abundant class of variants associated with signifi-
cant changes in gene expression both for somatically
derived (57/115 or 50 %) and germline derived SVs (26/
53 or 49 %). Although only 6 % ((573 + 232)/ (4516 +
5518); Fig. 1) of all SVs are associated with transloca-
tions, our transcriptional analysis indicates that they
are the most likely class of SVs to be associated with
changes in gene expression (Table 2; Additional file 2:
Figure S5; Additional file 9: Table S8).
Discussion
An integrated high-throughput computational work-
flow was employed to accurately detect a remarkably
large number (10,034) of SVs in cancerous tissue
samples isolated from 6 ovarian cancer patients. This
number is larger than previous estimates of the
number of SVs in other types of cancer tissues and
cell lines [8] possibly due to the greater accuracy
afforded by our de novo assembly approach and/or
because of the exceptional chromosomal instability
known to be associated with ovarian cancers [45].
The majority (5518) of these SVs were determined to
be of germline origin, reflective of the abundance of
naturally occurring SVs believed to be segregating in
human populations [46]. An additional large number
of the SVs (4516) identified in the ovarian cancer
samples were determined to be of somatic origin
Table 1 Summary of the number of the various types of SVs
detected in the DNA sequencing analysis and their expression
as detected by RNA-Seq or microarray studies (see text for details)






5′-truncated 167 29 NA
coding-gene-fusion 45 8 NA
Uncharacterized RNA 216 33 NA
alternative 5′UTR 30 1 7
alternative 3′UTR 47 2 14
Promoters 172 NA 21
Total 677 73 42
B: Germline derived
5′-truncated 41 10 NA
coding-gene-fusion 7 0 NA
Uncharacterized RNA 68 14 NA
alternative 5′UTR 15 1 5a
alternative 3′UTR 27 5 4a
Promoters 226 NA 16
Total 384 30 25
aOverlap between RNA-Seq and microarray detection
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arising de novo in the cancer cell lineage. Somatically
derived SVs have recently been reported to constitute a
major fraction of somatic tissue genetic variation in
humans [47] and our results are consistent with these find-
ings. Since our study was based on the analysis of only six
ovarian cancer patients and we employed a stringent set of
filtering criteria, our results likely constitute a relatively
conservative estimate of SVs that may be associated with
OC. Indeed, two recently identified OC gene fusion variants
[48, 49] were not among those identified in our study.
While a major fraction of the SVs identified in our study
were shown to map to unannotated regions of the genome
(gene deserts), the functional significance of these variants
is currently unknown. In contrast, intergenic SVs, while
constituting only 11 % of the SVs identified in our study,
are the basis of gene fusions- a well defined class of SVs
Table 2 Summary of the number of various functional classes of SVs across multiple structural classes of SVs
Somatically derived Germline derived
svClass SVs at DNA level Detected by RNA-Seq / differentially
expressed (microarray)
SVs at DNA level Detected by RNA-Seq / differentially
expressed (microarray)
Deletion 92 17 154 16
Insertion 13 2 0 0
Inversion 45 10 17 4
Inv-dupli 86 8 74 5
Tandem-dupli 49 21 7 2
Translocation 398 57 125 26
Transposition 4 0 7 0
Total 677 115 384 53
Fig. 6 Structure of six intergenic SVs resulting in “in-frame” coding gene fusions. The figure represents the structure of the gene fusion and
associated protein domains. Square boxes with numbers represent exons (5′ partner gene: blue, 3′ partner gene: orange), red lines represent the
fusion breakpoint, gene symbols and corresponding chromosomes (in parenthesis) are shown on top of each gene fusion structure)
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previously demonstrated to be of functional significance
in the onset and progression of a variety of cancers [6–8].
To our knowledge, ours is the first study to systematically
analyze both the presence and expression of SVs in the
same panel of cancer patient samples. Among the most
notable findings coming out of this comparative analysis is
the remarkably low proportion of cancer SVs that are being
transcribed. Only 20 % of the gene fusions detected in our
DNA-Seq analysis were detectable in the RNA-Seq analysis
of the same samples. Remarkably, none of the germline de-
rived gene fusions but all of the somatically derived gene fu-
sions were detectable on the RNA level. This observation
suggests the existence of a regulatory mechanism or mech-
anisms that may effectively suppress older, more
established germline SVs segregating in natural populations.
Such repression mechanisms may be lost or otherwise ren-
dered less effective in suppressing de novo variants arising
in cancer cell lineages. Consistent with this possibility is the
recent finding that a microRNA (miR-203) that targets and
suppresses expression of the BCR-ABL fusion protein is
hypermethylated in several hematopoietic tumors including
chronic myelogenous leukemias and some lymphoblastic
leukemias. Re-expression of this microRNA has been
shown to significantly reduce BCR-ABL fusion protein
levels and to coincidently inhibit tumor cell proliferation
[50]. The relevance of this and/or other regulatory mecha-
nisms to the fact that several gene fusions previously identi-
fied as biomarkers of cancer have recently been found to be
present in normal healthy individuals [51] remains to be
determined.
Further evidence of the importance of the regulation
of gene fusions and other SVs in cancer comes from
our microarray analyses. We found that only 10–30 %
of both germline and somatically derived fusions dis-
play a significant change in the expression of those
genes involved in the fusion relative to normal controls.
In several cases, changes in the expression of the pro-
tein coding domains involved in the fusions have been
previously associated with cancer onset or progression.
Conclusions
Collectively, our findings are consistent with the view
that gene fusions and other SVs may be significant
factors in the onset and progression of ovarian cancer.
Our results further suggest that it is not only the oc-
currence of these variants in cancers but their regula-
tion that contributes to their biological and clinical
significance.
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Contigs are mapped back to the reference genome and if split-mapping is
observed, a SV call is considered validated and breakpoints (shown in red)
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intergenic SVs. A. displays the distribution of somatically derived
intergenic SVs, B. displays the distribution of those somatically derived
intergenic SVs that were either transcribed (detected using RNA-Seq) or
resulted in differential gene-expression (measured using gene-expression
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